For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Personalized Treatments in HIV Prevention and Care: What Can We Do in 2015 After CROI?
with Dr. Emmanuelle Huchet and Pr. Jean-Michel Molina
- PrEP: a much greater efficacy that anticipated, according to the ANRS Ipergay trial
- Prevention and treatment: two inseparable components of a comprehensive strategy against HIV
- Criteria that we should now recommend when changing a patient’s treatment
- Preferred treatments to ensure tolerability in patients
This activity is supported
by an educational grant from:
Personalized HIV Treatments
Professor Jean-Michel Molina, head of the infectious diseases department at Saint-Louis Hospital in Paris and Scientific Director for the Ipergay trial in France, was invited to present the findings of this trial and discuss personalized treatments in HIV prevention and care.
The ANRS Ipergay trial not only demonstrated the high efficacy of PrEP (pre-exposure prophylaxis), a new tool to protect against HIV infection, but also that it helps bring people at risk into the healthcare system, people who are sometimes infected without knowing it, and therefore get screened, and treated.
In a comprehensive strategy to combat HIV, prevention and treatment strategies become inseparable.
Patients infected with HIV now have a large number of therapeutic options, all equally effective. They can choose their therapy based on criteria such as tolerance, drug interactions, lifestyle and personal preference.
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Emmanuelle Huchet, MD has a financial interest/relationship or affiliation with:
AbbVie, BMS, Gilead, Janssen, Merck, ViiV
Jean-Michel Molina, MD, PhD, PU-PH has a financial interest/relationship or affiliation in the form of:
Grants: Gilead Science, Merck. Advisory boards: Merck, Gilead, BMS, Janssen, ViiV, Abbvie
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.